<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411604</url>
  </required_header>
  <id_info>
    <org_study_id>Envarsus® 3007</org_study_id>
    <nct_id>NCT02411604</nct_id>
  </id_info>
  <brief_title>Expanded Access Study for Renal Transplant Patients With Envarsus XR ™</brief_title>
  <official_title>Expanded Access Study for Renal Transplant Patients With Envarsus XR™: Envarsus 3007</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veloxis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veloxis Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Open label, multi-center, expanded access study for renal transplant patients with once daily
      Envarsus XR (Tacrolimus).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to facilitate expanded access of Envarsus XR treatment to renal
      transplant patients. Patients are identified by the site investigator as a patient who has
      experienced favorable outcomes while in an Envarsus XR (LCP-Tacro) clinical study and/or the
      site investigator has identified a renal transplant patient with a medical need for an
      alternative tacrolimus treatment versus the patient's current tacrolimus treatment.
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Renal Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR.</description>
    <other_name>Envarsus XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible patients will fulfill all of the following criteria:

               1. Patient age ≥18years old

               2. Willing to give written informed consent and is able to speak, write and
                  understand English

               3. Patient understands potential risks or benefits with treatment of Envarsus XR

               4. Patients who have received a primary or secondary kidney transplant

               5. Patient who have received prior treatment with Envarsus XR (LCP-Tacro) and who
                  are not currently participating in an Envarsus/LCP-Tacro study OR

               6. The treating Investigator has identified the patient as having a medical
                  necessity for switching from their current tacrolimus treatment to Envarsus XR:
                  Investigator is aware the medical necessity for switching is not related to the
                  inability to purchase available tacrolimus.

        Exclusion Criteria:

          -  Patients fulfilling any of the following criteria are NOT eligible for study
             inclusion:

               1. Recipients of organ transplants other than kidney

               2. Pregnant or nursing (lactating) women, or planning to become pregnant, where
                  pregnancy is defined as a state of female after conception and until the
                  termination of gestation, confirmed by a positive hCG serum or urine laboratory
                  test.

               3. Women of child-bearing potential, defined as all women physiologically capable of
                  becoming pregnant who are unwilling to use a defined SOC method of contraception,
                  UNLESS they are

          -  Women whose career, lifestyle, or sexual orientation preclude intercourse with a male
             partner

          -  Women whose partners have been sterilized by vasectomy or other medically approved
             means
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

